North America

Corporate earnings, M&A, IPOs, and business developments across North American markets.

Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

by

Presented interim FRONTIER4 data evaluate the long-term safety and efficacy of investigational denecimig across once-weekly, once-every-two-weeks, and once-monthly dosing in hemophilia A participants of all ages and disease severities1,2 Denecimig is an investigational subcutaneous… Source: prnewswire Country: United States

Discovery Announces Details of Second Quarter 2026 Results Conference Call and Webcast

by

TORONTO, July 11, 2026 (GLOBE NEWSWIRE) — Discovery Mining Ltd. (TSX: DSV, OTCQX: DSVSF) (“ Discovery ” or the “ Company ”) today announced that the Company will release its financial and operating results for the second quarter of 2026 prior to the market open on Thursday, August 13, 2026, Eastern Time (“ET”). The Company … Read more